Boyd Biomedical, Inc.

© 2026 Boyd Biomedical, Inc.

commercial-phases_LBB_phase-1_clinical-evidence_color_800x800
Phase 1

Clinical Evidence

We help you turn first human data into scientific credibility. Early results build conviction only when they answer the right questions and reach the clinicians, payers, and investors who need to see them.

×

Please feel out the form below and someone from our team will contact you shortly.
Phase overview

Clinical Evidence is the phase where you generate your first human data, typically through feasibility studies, pilot trials, or early clinical investigations under IRB approval. The goal is not definitive regulatory evidence but proof-of-concept data that attracts investment, engages clinical partners, and builds scientific credibility. Patient numbers are small, study designs are exploratory, and the primary audiences are investors and key opinion leaders. Whether you are pursuing a 510(k), De Novo, or PMA pathway, early clinical data plays a critical role in building stakeholder conviction.

What happens in this phase

Each phase draws on a different combination of our disciplines and sub-disciplines. These are the ones that turn early clinical data into credibility with the stakeholders who matter most.

Evidence Planning

An evidence strategy that addresses what clinicians, payers, and buyers will need to see.

Medical Affairs

Identification and engagement of the key opinion leaders whose support matters most.

Market Research

Primary research with clinical stakeholders to test assumptions and inform strategy.

Patient Engagement

Trial recruitment and retention strategies that keep studies on schedule.

Market & Investor Strategy

An investor narrative updated with proof-of-concept data to support the raise that funds pivotal work.

Reimbursement

Early identification of the economic data payers will require.

_BK25118_1 Color (800 x 800)
What you walk away with

You leave Clinical Evidence with an evidence strategy built around what clinicians, payers, and buyers need to see, and with key opinion leaders identified and engaged. You also have primary research that tests your commercial assumptions, a recruitment and retention strategy for your studies, an investor narrative grounded in human data, and a clear view of the economic evidence payers will expect.

Why this phase matters

Early data rarely speaks for itself. How results are framed, who endorses them, and whether studies collect the right data all determine whether the program looks promising or underpowered. Evidence gaps found later are expensive to close, and claims made too early can carry into regulatory review.

commercial-phases_LBB_phase-2_pivotal-development_color_800x800
NEXT PHASE

Pivotal Development

With proof of concept and clinical relationships in place, the program moves into the definitive technical, regulatory, and clinical work that supports submission.

×

Please feel out the form below and someone from our team will contact you shortly.
Content Card - Just Mighty - Launch - Two Color - Full (1920 x 1080)
Logo - Just Mighty - White Logo (400 x 400)

Your innovation Just Might change the world. But is your strategy up to the task? We help you turn Just Might into Just Mighty.